WATERTOWN, Mass. – June 17, 2015 – FORMA Therapeutics announced today the achievement of several discovery milestones in their alliance with Boehringer Ingelheim (BI) for the discovery of novel drug candidates against protein-protein interactions (PPI) for the treatment of cancer. Financial milestones payable to FORMA for this achievement have not been disclosed.

“FORMA’s continued successes within the BI partnership, an agreement originally announced in January 2012 and with milestones achieved in 2014, underscore our ability to make tractable progress in the challenging area of protein-protein interactions,” said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. “Investment in creative and talented individuals, as well as fully exploiting various technology platforms, has provided FORMA with keen insights into three-dimensional protein structure and druggable binding pockets. We are quite pleased to have contributed to BI’s drug discovery pipeline by identifying a panel of novel scaffolds across multiple targets.”

About FORMA
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com

Join our conversation on Twitter @FORMAInc.

Media Contact
For FORMA Therapeutics
Kari Watson, +1 781-235-3060
kwatson@macbiocom.com
MacDougall Biomedical Communications